West Pharmaceutical Services, Inc. (NYSE:WST) has earned an average rating of “Hold” from the six research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $107.00.

A number of brokerages have recently issued reports on WST. Stephens began coverage on West Pharmaceutical Services in a research report on Tuesday. They set an “equal weight” rating and a $99.00 target price on the stock. Zacks Investment Research upgraded West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Wednesday, September 27th. Jefferies Group LLC upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and increased their target price for the company from $96.00 to $115.00 in a research report on Friday, September 15th. Finally, BidaskClub lowered West Pharmaceutical Services from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 3rd.

Hedge funds have recently made changes to their positions in the business. Acrospire Investment Management LLC purchased a new position in West Pharmaceutical Services in the 2nd quarter valued at $113,000. Citigroup Inc. lifted its holdings in West Pharmaceutical Services by 95.1% in the 2nd quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock valued at $148,000 after purchasing an additional 765 shares in the last quarter. Wolverine Trading LLC purchased a new position in West Pharmaceutical Services in the 2nd quarter valued at $200,000. Nomura Holdings Inc. purchased a new position in West Pharmaceutical Services in the 2nd quarter valued at $201,000. Finally, Bradley Foster & Sargent Inc. CT purchased a new position in West Pharmaceutical Services in the 2nd quarter valued at $212,000. Institutional investors own 90.57% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/06/west-pharmaceutical-services-inc-wst-receives-107-00-consensus-target-price-from-analysts.html.

West Pharmaceutical Services (NYSE:WST) traded up 0.97% during trading on Tuesday, hitting $95.76. 107,271 shares of the stock traded hands. The stock has a 50 day moving average price of $90.88 and a 200-day moving average price of $90.62. The stock has a market cap of $7.09 billion, a P/E ratio of 41.10 and a beta of 1.12. West Pharmaceutical Services has a 52-week low of $70.17 and a 52-week high of $99.91.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.01. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. The firm had revenue of $397.60 million for the quarter, compared to analyst estimates of $406.00 million. During the same quarter last year, the firm posted $0.59 EPS. The business’s revenue was up 2.5% on a year-over-year basis. On average, analysts anticipate that West Pharmaceutical Services will post $2.68 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Wednesday, October 18th will be given a dividend of $0.14 per share. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.13. The ex-dividend date of this dividend is Tuesday, October 17th. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.59%. West Pharmaceutical Services’s dividend payout ratio (DPR) is 22.22%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Receive News & Stock Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related stocks with our FREE daily email newsletter.